Holomycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-00966 |
CAS | 488-04-0 |
Molecular Weight | 214.26 |
Molecular Formula | C7H6N2O2S2 |
Purity | >98% |
Online Inquiry
Description
Holomycin is a sulfur-containing nitrogen-containing heterocyclic antibiotic produced by Streptomyces griseus. It has anti-gram-positive bacteria, negative bacteria, fungi and protozoa activity.
Specification
Synonyms | N-Demethylthiolutin |
Storage | Store at -20 °C |
IUPAC Name | N-(5-oxo-4H-dithiolo[4,3-b]pyrrol-6-yl)acetamide |
Canonical SMILES | CC(=O)NC1=C2C(=CSS2)NC1=O |
InChI | InChI=1S/C7H6N2O2S2/c1-3(10)8-5-6-4(2-12-13-6)9-7(5)11/h2H,1H3,(H,8,10)(H,9,11) |
InChI Key | HBUNPJGMNVQSBX-UHFFFAOYSA-N |
Properties
Appearance | Orange Yellow Flake Crystal |
Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria; fungi; parasites |
Boiling Point | 532.147°C at 760 mmHg |
Melting Point | 264-271°C(dec.) |
Density | 1.632 g/cm3 |
Solubility | Soluble in DMSO |
Reference Reading
1. Saccharothrix algeriensis NRRL B-24137, the first non-Streptomyces actinobacterium, produces holomycin after cystine feeding
Rabiâa Merrouche, Amine Yekkour, Yannick Coppel, Noureddine Bouras, Abdelghani Zitouni, Florence Mathieu, Nasserdine Sabaou Arch Microbiol. 2020 Nov;202(9):2509-2516. doi: 10.1007/s00203-020-01971-3. Epub 2020 Jul 8.
Saccharothrix algeriensis NRRL B-24137 is an actinobacterium isolated from Algerian Saharan soil. This strain has the ability to produce several dithiolopyrrolone antibiotic derivatives depending on the precursors added to the culture medium. This group of antibiotics is known for their potent antimicrobial and anticancer activities. Holomycin is a member of the dithiolopyrrolone group of antibiotics, and has already been isolated from several species of actinobacteria belonging to the genus Streptomyces and also from some Gram-negative bacteria. In this study, holomycin was produced for the first time in the culture broth of a non-Streptomyces actinobacteria. This antibiotic was induced by adding 5 mM of L-cystine as precursor to the semi-synthetic fermentation broth of Sa. algeriensis NRRL B-24137 and then fully identified after HPLC purification. The minimum inhibitory concentrations (MIC) of holomycin were determined against several pathogenic microorganisms, including Escherichia coli ATCC 10536 Klebsiella pneumoniae CIP 82.91, Listeria monocytogenes CIP 82110, Staphylococcus aureus CIP 7625, Aspergillus carbonarius M333, Fusarium culmorum FC1, Candida albicans IPA 200. This antibiotic showed a broad-spectrum antimicrobial activity, inhibiting a variety of Gram-positive and Gram-negative bacteria, and micro-fungi.
2. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases
Guang-Ming Ren, Jian Li, Xiao-Chun Zhang, Yu Wang, Yang Xiao, Xuan-Yi Zhang, Xian Liu, Wen Zhang, Wen-Bing Ma, Jie Zhang, Ya-Ting Li, Shou-Song Tao, Ting Wang, Kai Liu, Hui Chen, Yi-Qun Zhan, Miao Yu, Chang-Yan Li, Chang-Hui Ge, Bo-Xue Tian, Gui-Fang Dou, Xiao-Ming Yang, Rong-Hua Yin Sci Immunol. 2021 Apr 30;6(58):eabe2933. doi: 10.1126/sciimmunol.abe2933.
Pharmacologically inhibiting nucleotide-binding domain and leucine-rich repeat-containing (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome activation results in potent therapeutic effects in a wide variety of preclinical inflammatory disease models. NLRP3 deubiquitination is essential for efficient NLRP3 inflammasome activity, but it remains unclear whether this process can be harnessed for therapeutic benefit. Here, we show that thiolutin (THL), an inhibitor of the JAB1/MPN/Mov34 (JAMM) domain-containing metalloprotease, blocks NLRP3 inflammasome activation by canonical, noncanonical, alternative, and transcription-independent pathways at nanomolar concentrations. In addition, THL potently inhibited the activation of multiple NLRP3 mutants linked with cryopyrin-associated periodic syndromes (CAPS). Treatment with THL alleviated NLRP3-related diseases in mouse models of lipopolysaccharide-induced sepsis, monosodium urate-induced peritonitis, experimental autoimmune encephalomyelitis, CAPS, and methionine-choline-deficient diet-induced nonalcoholic fatty liver disease. Mechanistic studies revealed that THL inhibits the BRCC3-containing isopeptidase complex (BRISC)-mediated NLRP3 deubiquitination and activation. In addition, we show that holomycin, a natural methyl derivative of THL, displays an even higher inhibitory activity against NLRP3 inflammasome than THL. Our study validates that posttranslational modification of NLRP3 can be pharmacologically targeted to prevent or treat NLRP3-associated inflammatory diseases. Future clinical development of derivatives of THL may provide new therapies for NLRP3-related diseases.
3. Holomycin, an Antibiotic Secondary Metabolite, Is Required for Biofilm Formation by the Native Producer Photobacterium galatheae S2753
Sheng-Da Zhang, Thomas Isbrandt, Laura Louise Lindqvist, Thomas Ostenfeld Larsen, Lone Gram Appl Environ Microbiol. 2021 May 11;87(11):e00169-21. doi: 10.1128/AEM.00169-21. Print 2021 May 11.
While the effects of antibiotics on microorganisms are widely studied, it remains less well understood how antibiotics affect the physiology of the native producing organisms. Here, using a marine bacterium, Photobacterium galatheae S2753, that produces the antibiotic holomycin, we generated a holomycin-deficient strain by in-frame deletion of hlmE, the core gene responsible for holomycin production. Mass spectrometry analysis of cell extracts confirmed that the ΔhlmE strain did not produce holomycin and that the mutant was devoid of antibacterial activity. Biofilm formation of the ΔhlmE strain was significantly reduced compared to that of wild-type S2753 and was restored in an hlmE complementary mutant. Consistent with this, exogenous holomycin, but not its dimethylated and less antibacterial derivative, S,S'-dimethyl holomycin, restored the biofilm formation of the ΔhlmE strain. Furthermore, zinc starvation was found to be essential for both holomycin production and biofilm formation of S2753, although the molecular mechanism remains elusive. Collectively, these data suggest that holomycin promotes biofilm formation of S2753 via its ene-disulfide group. Lastly, the addition of holomycin at subinhibitory concentrations also enhanced the biofilms of four other Vibrionaceae strains. P. galatheae likely gains an ecological advantage from producing holomycin as both an antibiotic and a biofilm stimulator, which facilitates nutrition acquisition and protects P. galatheae from environmental stresses. Studying the function of antibiotic compounds in the native producer will shed light on their roles in nature and could point to novel bioprospecting strategies.IMPORTANCE Despite the societal impact of antibiotics, their ecological functions remain elusive and have mostly been studied by exposing nonproducing bacteria to subinhibitory concentrations. Here, we studied the effects of the antibiotic holomycin on its native producer, Photobacterium galatheae S2753, a Vibrionaceae bacterium. Holomycin provides a distinct advantage to S2753 both as an antibiotic and by enhancing biofilm formation in the producer. Vibrionaceae species successfully thrive in global marine ecosystems, where they play critical ecological roles as free-living, symbiotic, or pathogenic bacteria. Genome mining has demonstrated that many have the potential to produce several bioactive compounds, including P. galatheae To unravel the contribution of the microbial metabolites to the development of marine microbial ecosystems, better insight into the function of these compounds in the producing organisms is needed. Our finding provides a model to pursue this and highlights the ecological importance of antibiotics to the fitness of the producing organisms.
Recommended Products
BBF-05734 | Irofulven | Inquiry |
BBF-03868 | Honokiol | Inquiry |
BBF-03963 | Pristinamycin | Inquiry |
BBF-03921 | Staurosporine | Inquiry |
BBF-01210 | Emericid | Inquiry |
BBF-01729 | Hygromycin B | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳